Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey

被引:21
作者
Mutevedzi, Portia Chipo [1 ]
Kawonga, Mary [2 ]
Kwatra, Gaurav [1 ,3 ,4 ]
Moultrie, Andrew [1 ]
Baillie, Vicky [1 ]
Mabena, Nicoletta [5 ]
Mathibe, Masego Nicole [1 ]
Rafuma, Martin Mosotho [1 ]
Maposa, Innocent [6 ]
Abbott, Geoff [7 ]
Hugo, Janie [7 ]
Ikalafeng, Bridget [8 ]
Adelekan, Tsholofelo [8 ]
Lukhele, Mkhululi [9 ]
Madhi, Shabir A. [1 ,3 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, South African Med Res Council Vaccines & Infect D, Johannesburg, South Africa
[2] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Dept Community Hlth, Johannesburg, South Africa
[3] Univ Witwatersrand, Fac Hlth Sci, African Leadership Vaccinol Expertise, Johannesburg, South Africa
[4] Christian Med Coll & Hosp, Dept Clin Microbiol, Vellore, Tamil Nadu, India
[5] ResearchLinkME, Johannesburg, South Africa
[6] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Epidemiol & Biostat, Johannesburg, South Africa
[7] Univ Pretoria, Dept Family Med, Community Oriented Primary Care Res Unit, Pretoria, South Africa
[8] Gauteng Dept Hlth, Johannesburg, South Africa
[9] Univ Witwatersrand, Div Orthoped, Johannesburg, South Africa
关键词
COVID-19; SARS-CoV-2; coronavirus; seroprevalence; serosurvey; infection-mortality risk; ANTI-SARS-COV-2 IGG ANTIBODIES; SEROPREVALENCE; PREVALENCE;
D O I
10.1093/ije/dyab217
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Limitations in laboratory testing capacity undermine the ability to quantify the overall burden of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Methods We undertook a population-based serosurvey for SARS-CoV-2 infection in 26 subdistricts, Gauteng Province (population 15.9 million), South Africa, to estimate SARS-CoV-2 infection, infection fatality rate (IFR) triangulating seroprevalence, recorded COVID-19 deaths and excess-mortality data. We employed three-stage random household sampling with a selection probability proportional to the subdistrict size, stratifying the subdistrict census-sampling frame by housing type and then selecting households from selected clusters. The survey started on 4 November 2020, 8 weeks after the end of the first wave (SARS-CoV-2 nucleic acid amplification test positivity had declined to <10% for the first wave) and coincided with the peak of the second wave. The last sampling was performed on 22 January 2021, which was 9 weeks after the SARS-CoV-2 resurgence. Serum SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin-G (IgG) was measured using a quantitative assay on the Luminex platform. Results From 6332 individuals in 3453 households, the overall RBD IgG seroprevalence was 19.1% [95% confidence interval (CI): 18.1-20.1%] and similar in children and adults. The seroprevalence varied from 5.5% to 43.2% across subdistricts. Conservatively, there were 2 897 120 (95% CI: 2 743 907-3 056 866) SARS-CoV-2 infections, yielding an infection rate of 19 090 per 100 000 until 9 January 2021, when 330 336 COVID-19 cases were recorded. The estimated IFR using recorded COVID-19 deaths (n = 8198) was 0.28% (95% CI: 0.27-0.30) and 0.67% (95% CI: 0.64-0.71) assuming 90% of modelled natural excess deaths were due to COVID-19 (n = 21 582). Notably, 53.8% (65/122) of individuals with previous self-reported confirmed SARS-CoV-2 infection were RBD IgG seronegative. Conclusions The calculated number of SARS-CoV-2 infections was 7.8-fold greater than the recorded COVID-19 cases. The calculated SARS-CoV-2 IFR varied 2.39-fold when calculated using reported COVID-19 deaths (0.28%) compared with excess-mortality-derived COVID-19-attributable deaths (0.67%). Waning RBD IgG may have inadvertently underestimated the number of SARS-CoV-2 infections and conversely overestimated the mortality risk. Epidemic preparedness and response planning for future COVID-19 waves will need to consider the true magnitude of infections, paying close attention to excess-mortality trends rather than absolute reported COVID-19 deaths.
引用
收藏
页码:404 / 417
页数:14
相关论文
共 35 条
  • [1] Africa Centres for Disease Control and Prevention, 2020, GEN PROT POP BAS AG
  • [2] The Power of Antibody-Based Surveillance
    Alter, Galit
    Seder, Robert
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18) : 1782 - 1784
  • [3] Coronavirus outbreak in Nigeria: Burden and socio-medical response during the first 100 days
    Amzat, Jimoh
    Aminu, Kafayat
    Kolo, Victor, I
    Akinyele, Ayodele A.
    Ogundairo, Janet A.
    Danjibo, Maryann C.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 98 : 218 - 224
  • [4] COVID-19 antibody seroprevalence in Santa Clara County, California
    Bendavid, Eran
    Mulaney, Bianca
    Sood, Neeraj
    Shah, Soleil
    Bromley-Dulfano, Rebecca
    Lai, Cara
    Weissberg, Zoe
    Saavedra-Walker, Rodrigo
    Tedrow, Jim
    Bogan, Andrew
    Kupiec, Thomas
    Eichner, Daniel
    Gupta, Ribhav
    Ioannidis, John P. A.
    Bhattacharya, Jay
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2021, 50 (02) : 410 - 419
  • [5] Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review
    Byambasuren, Oyungerel
    Dobler, Claudia C.
    Bell, Katy
    Rojas, Diana Patricia
    Clark, Justin
    Mclaws, Mary-Louise
    Glasziou, Paul
    [J]. PLOS ONE, 2021, 16 (04):
  • [6] Centres for Disease Control and Prevention, 2020, SER TEST COVID 19
  • [7] Chen XH, 2021, LANCET GLOB HEALTH, V9, pE598, DOI [10.1016/S2214-109X(21)00026-7, 10.1101/2020.09.11.20192773]
  • [8] Gronvall G., 2020, DEVELOPING NATL STRA
  • [9] The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis
    Guelsen, Askin
    Yigitbas, Burcu Arpinar
    Uslu, Berat
    Droemann, Daniel
    Kilinc, Oguz
    [J]. PULMONARY MEDICINE, 2020, 2020
  • [10] SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys
    Hallal, Pedro C.
    Hartwig, Fernando P.
    Horta, Bernardo L.
    Silveira, Mariangela F.
    Struchiner, Claudio J.
    Vidaletti, Luis P.
    Neumann, Nelson A.
    Pellanda, Lucia C.
    Dellagostin, Odir A.
    Burattini, Marcelo N.
    Victora, Gabriel D.
    Menezes, Ana M. B.
    Barros, Fernando C.
    Barros, Aluisio J. D.
    Victora, Cesar G.
    [J]. LANCET GLOBAL HEALTH, 2020, 8 (11): : E1390 - E1398